TAGHAVI N, AFZALI H, SOHRABPOUR H. STUDY ON THE HEPATOTOXICITY OF ANTI-TUBERCULOSIS DRUGS IN 190 PATIE NTS WITH PULMONARY AND E XTRAPULMONARY TUBERCULOSIS. Med J Islam Repub Iran 2004; 17 (4) :271-275
URL:
http://mjiri.iums.ac.ir/article-1-663-en.html
From the Department of Infectious Disease. Boo-Ali Hospital. Shahid Beheshti University of Medical Sciences
Abstract: (5284 Views)
Tuberculosis is one of the oldest diseases that affects humans. The cause of this
disease is Mycobacterium tuberculosis. This disease affects approximately 8.8 million
people worldwide and led to over 3 million deaths in 1995.
95% of those affected and 98% of deaths occurred in developing countries. Hepatic
reactions constitute a major proportion of drug reactions to antituberculosis drugs
being reported in 4% of cases treated with rifampin/isoniazid and pyrazinamide in the
US A and 8-50% in India and developing countries.
For the purpose of identifying the hepatotoxicity of anti-tuberculous drugs, this
study was performed in hospitals affiliated to Shahid Beheshti University in Tehran
during 1994 to 1997.
The current descriptive study was performed on hospitalized patients diagnosed
as having active tuberculosis.
History was taken from all the patients and clinical signs were recorded. Three
sputum samples for mycobacterial acid fast stain examination and cultures (three consecutive
days) were sent to Pasteur Institute. Liver function tests (AST, ALT, alkaline
phosphatase, bilirubin, PT) were performed before treatment and repeated weekly for
two weeks then two weekly for the first two months and then monthly until the end of
treatment.
From a total of 262 patients during the study, 190 patients were studied. 51 %
were male and the rest were female.
The lowest rate of TB was in the age group less than 5 and the most frequent rate
ofTB was in the 56-65 years age group. 107 patients (56.2%) had active pulmonary
tuberculosis and 43.7% had extra-pulmonary TB. 44.2% had positive smear sputum,
22.1 % had positive biopsy, and 33.6% were diagnosed based on clinical findings, xrays
and other paraclinical tests. 25.7% of patients had increased ALT and AST following
the treatment, and in 4.7% of cases the increase was 4-5 times normal and in
3.6% 5 times normal, 8.4% had increase in bilirubin and 6.8% had increase in bilirubin
associated with increase in ALT and AST, 8.4% had increased alkaline phosphatase
and 7.6% had disturbance in PT.
Considering that 25.7% of the patients had increased levels of liver enzymes and
in 3.6% of them the increased level exceeded 5 times that of normal and also 6 cases of
7 were over 35 years old, therefore, anti-tuberculosis drug consumption, must be considered
more seriously in patients over the age of 35.